Poniard Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:PARD)

$0.04 +0.00 (+2.33 %)
(As of 02/20/2018 10:32 AM ET)
Previous Close$0.04
Today's Range$0.04 - $0.04
52-Week Range$0.04 - $0.21
Volume100 shs
Average Volume5,178 shs
Market Capitalization$70,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.95

About Poniard Pharmaceuticals (OTCMKTS:PARD)

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of oncology products to impact the lives of people with cancer. It develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The Company has offices in San Francisco, California; and Seattle, Washington in United States.

Receive PARD News and Ratings via Email

Sign-up to receive the latest news and ratings for PARD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PARD
CUSIPN/A
Phone206-286-2501

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,500,000

Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions

What is Poniard Pharmaceuticals' stock symbol?

Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."

Who are some of Poniard Pharmaceuticals' key competitors?

Who are Poniard Pharmaceuticals' key executives?

Poniard Pharmaceuticals' management team includes the folowing people:

  • Ronald A. Martell, Chairman of the Board (Age 54)
  • Robert S. Basso, Independent Director (Age 67)
  • Frederick B. Craves Ph.D., Independent Director (Age 70)
  • Carl S. Goldfischer M.D., Independent Director (Age 58)
  • Robert M. Littauer, Independent Director (Age 56)
  • David R. Stevens Ph.D., Independent Director (Age 67)

How do I buy Poniard Pharmaceuticals stock?

Shares of Poniard Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Poniard Pharmaceuticals' stock price today?

One share of Poniard Pharmaceuticals stock can currently be purchased for approximately $0.04.

How big of a company is Poniard Pharmaceuticals?

Poniard Pharmaceuticals has a market capitalization of $70,000.00.

How can I contact Poniard Pharmaceuticals?

Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]


MarketBeat Community Rating for Poniard Pharmaceuticals (PARD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Poniard Pharmaceuticals (OTCMKTS:PARD) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Poniard Pharmaceuticals (OTCMKTS:PARD) Earnings History and Estimates Chart

Earnings by Quarter for Poniard Pharmaceuticals (OTCMKTS:PARD)

Poniard Pharmaceuticals (OTCMKTS PARD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2011Q3 2011($2.56)ViewN/AView Earnings Details
8/12/2011Q2 2011($2.40)($2.64)ViewN/AView Earnings Details
5/13/2011Q1 2011($2.40)($2.44)ViewN/AView Earnings Details
3/30/2011Q4 2010($5.20)($3.40)ViewN/AView Earnings Details
11/9/2010Q3 2010($6.80)($5.36)ViewN/AView Earnings Details
8/9/2010Q2 2010($7.60)($5.56)ViewN/AView Earnings Details
5/10/2010Q1 2010($9.20)($10.04)ViewN/AView Earnings Details
3/8/2010Q4 2009($9.20)($12.80)ViewN/AView Earnings Details
11/3/2009Q3 2009($12.00)($11.52)ViewN/AView Earnings Details
8/4/2009Q2 2009($13.60)($11.36)ViewN/AView Earnings Details
5/5/2009Q1 2009($15.20)($13.84)ViewN/AView Earnings Details
3/16/2009Q4 2008($15.20)($16.24)ViewN/AView Earnings Details
10/30/2008Q3 2008($13.20)($14.24)ViewN/AView Earnings Details
7/31/2008Q2 2008($12.40)($14.60)ViewN/AView Earnings Details
5/6/2008Q1 2008($12.80)($11.52)ViewN/AView Earnings Details
2/28/2008Q4 2007($10.80)($11.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Poniard Pharmaceuticals (OTCMKTS:PARD) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Poniard Pharmaceuticals (OTCMKTS:PARD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Poniard Pharmaceuticals (OTCMKTS PARD)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Poniard Pharmaceuticals (OTCMKTS PARD) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Poniard Pharmaceuticals (OTCMKTS:PARD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Poniard Pharmaceuticals (OTCMKTS:PARD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Poniard Pharmaceuticals (OTCMKTS PARD) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.